Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT06376253
PHASE1

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-EVS459 and the safety and imaging properties of \[68Ga\]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (non-sq. NSCLC).

Official title: A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

4

Start Date

2024-09-08

Completion Date

2025-07-10

Last Updated

2026-06-23

Healthy Volunteers

No

Interventions

DRUG

[68Ga]Ga-EVS459

Radioligand imaging agent

DRUG

[177Lu]Lu-EVS459

Radioligand therapy

Locations (1)

Novartis Investigative Site

Tel Aviv, Israel